Management challenges in muscle‐specific tyrosine kinase myasthenia gravis
- 17 December 2012
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1274 (1), 86-91
- https://doi.org/10.1111/j.1749-6632.2012.06781.x
Abstract
Myasthenia gravis with antibodies to muscle-specific tyrosine kinase (MuSK-MG) is generally considered a severe disease because of the associated weakness distribution with prevalent involvement of bulbar muscles and a rapidly progressive course and early respiratory crises. Its treatment can be unrewarding, owing to poor response to acetylcholinesterase inhibitors in most patients, disease relapses in spite of high-dose immunosuppression, and development of permanent bulbar weakness. High-dose prednisone plus plasma exchange is the recommended approach for treating rapidly progressive bulbar weakness. In the disease management, oral steroids proved effective, plasma exchange produced marked, albeit short-term, improvement, while conventional immunosuppressants were comparatively less effective. Rituximab is a promising treatment for refractory MuSK-MG; in uncontrolled studies, nearly all treated patients achieved significant improvement with substantial decrease of medication. It is yet to be clarified whether the early use of rituximab could prevent the permanent bulbar weakness, which constitutes a relevant disability in these patients.Keywords
This publication has 58 references indexed in Scilit:
- Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravisJournal of Neuroimmunology, 2012
- Antibodies against Muscle-Specific Kinase Impair Both Presynaptic and Postsynaptic Functions in a Murine Model of Myasthenia GravisThe American Journal of Pathology, 2012
- Anti-MuSK autoantibodies block binding of collagen Q to MuSKNeurology, 2011
- Response of patients with refractory myasthenia gravis to rituximab: a retrospective studyTherapeutic Advances in Neurological Disorders, 2011
- B‐cell targeted therapies in human autoimmune diseases: an updated perspectiveImmunological Reviews, 2010
- MuSK-antibody-positive myasthenia gravis in a South Asian populationJournal of the Neurological Sciences, 2009
- Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis Current StatusJournal of Clinical Neurology, 2009
- Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2006
- High‐dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodiesMuscle & Nerve, 2005